In parts of sub-Saharan Africa, child mortality remains alarmingly high—roughly one in ten children does not survive past the age of five. The main drivers include unsafe drinking water, malnutrition, malaria, and a lack of basic healthcare infrastructure.
In recent years, a simple public health intervention has shown remarkable promise: administering the antibiotic azithromycin to children twice a year. Clinical studies indicate that this approach can reduce child mortality by about 15%, with the strongest benefits observed among infants. In response, the World Health Organization (WHO) issued guidelines in 2020 recommending the measure for infants aged 1–11 months in high-mortality regions, while stressing the importance of monitoring antibiotic resistance.
Azithromycin, a broad-spectrum antibiotic, not only treats bacterial infections but also inhibits the replication of malaria parasites. In Ethiopia, researchers first noticed a nearly 50% drop in child deaths among communities receiving the drug. Subsequent studies across three countries confirmed that regular administration to children aged 1–59 months could reduce mortality by 13.5%.
Despite these encouraging results, experts warn that the widespread use of antibiotics carries serious risks. Surveillance data reveal rising antibiotic resistance genes and even cross-community transmission in mass-treatment areas. Some scientists argue that resistance can be reversible and note that most programs now include resistance monitoring. However, losing the effectiveness of azithromycin—a vital drug in resource-poor regions such as West Africa—could have devastating consequences.
Researchers emphasize that sustainable progress in child health will require more than drug-based interventions. Persistent reliance on mass medication highlights deeper gaps in access to clean water, adequate nutrition, and vaccination. Striking a balance between saving lives today and safeguarding public health for the future has become a critical global challenge.